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Abstract
Background: This paper reports the outcome of gefitinib for Chinese advanced NSCLC patients
with poor performance status (PS) at the Peking Union Medical College Hospital.
Methods: From Oct 2002 to Apr. 2006, 42 advanced NSCLC patients with PS 3/4 received
gefitinib 250 mg/day treatment. Median survival (MS) were calculated using the Kaplan-Meier
method and a Cox regression model was used to find main factors affecting MS.
Results: Adverse events (AEs) were generally mild (grade 1 and 2) and reversible. The most
frequent AEs were rash 72.2% (26/42) and diarrhea 44.4% (26/42). The objective tumor response
rate and stable disease rate were 40.5% and 26.2% respectively, and median survival(MS) of all
patients was 10.1 months (95% confidential interval CI, 3.4 ~ 16.8), and progression-free
survival(PFS) was 5.7 months (95% CI, 4.5 ~ 6.9). The MS were significantly related with objective
response of gefitinib. Objective responses was significantly related with rashes induced with
gefitinib.
Conclusion: Our study suggest that treatment with gefitinib may be well tolerated and beneficial
for Chinese patients with poor PS, and the safety and efficacy were similar to patients with good PS.
Background
Lung cancer is the leading cause of cancer deaths world-
wide. Platinum-based chemotherapy can improve the sur-
vival and quality of life for locally advanced and
metastatic lung cancer, and the median survival (MS) is
about 8 months[1]. Single agent chemotherapy is recom-
mended for patients with an Eastern Cooperation Oncol-
ogy Group (ECOG) performance status (PS) of 2 and only
best supportive care for patients with ECOG PS worse
than 2 because of toxicity of chemotherapy. Epidermal
growth factor receptor (EGFR) is important in the growth,
metastasis, and angiogenesis in NSCLC. Gefitinib (Iressa)
is a HER1/EGFR-tyrosine kinase inhibitor for treating
patients with non-small cell lung cancer (NSCLC)[2,3].
Two large randomized phase II trials proved the efficacy of
gefitinib in pretreated NSCLC patients after relapsing or
failing to chemotherapy, with response rates ranged
between 10–18.4%[4,5]. As gefitinib has a good safety
profile, it had been used in the treatment of patients with
ECOG PS of 3–4. Current data show that the efficacy of
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gefitinib differs much among people of different ethnic
origin, and in this paper, we retrospectively reviewed the
efficacy and safety of gefitinib in NSCLC patients with PS
3–4 at Peking Union Medical College Hospital in China.
Methods
Patients
We surveyed all the patients with NSCLC treated with
gefitinib between October 2002 and October 2004 at
Peking Union Medical College Hospital. Patients must be
18 years and older with cytology/histopathology-con-
firmed NSCLC and clinical stages IIIb and IV, and with
ECOG PS of 3–4 not fit for surgery, radiotherapy or chem-
otherapy. Other eligibility criteria included: adequate
bone marrow function (absolute neutrophil count > 1.5 ×
109/L, platelet count > 100 × 109/L and hemoglobin level
> 8.0 g/L), proper liver function (total bilirubin < 1.5 fold
of the upper limit of normal value, aspartate ami-
notransaminase (AST) and alkanine aminotransferase
(ALT) < 2.5 fold of the upper limit of normal value), and
adequate renal function (serum creatinine < 1.5 mg/dl,
blood urea nitrogen < 20 mg/dl). Exclusion criteria
included: uncontrolled central nerves system metastases,
severe underlying cardio-pulmonary diseases including
interstitial pneumonia, habitual diarrhea or constipation
and other GI disorders affecting drug absorption. All
patients came from clinical trial "Iressa Expanded Access
Program (EAP)", which was approved by United States
Food and Drug Administration (ClinicalTrials.gov Identi-
fier: NCT00034879). All patients must have written
informed consent form.
Study protocols
One oral gefitinib tablet (250 mg) was taken at about the
same time each day without interruption till the occur-
rence of unacceptable toxicity, disease progression or
death. Baseline evaluation was performed within 21 days
prior to enrollment, including complete medical history
and physical examination, laboratory tests (whole blood
counts, urine analysis, liver and renal functions), electro-
cardiogram, thorax computed-tomography (CT) scan,
radionuclide bone scan. The primary end point was sur-
vival, and the secondary end points were objective
response rate according to the RECIST criteria and pro-
gression free survival (PFS). Changes in 3 key symptoms
related to lung cancer, including cough, dyspnea and
pain, were also recorded. All adverse events were recorded
according to National Cancer Institute expanded com-
mon toxicity criteria(CTC), version 3.0.
Statistical analysis
Median overall survival (MS) and median PFS were calcu-
lated using the Kaplan-Meier method and a Cox regres-
sion model was used to find main factors affecting MS.
The factors considered for inclusion in the analyses were
age, sex, smoking status, ECOG PS, histology type, bone
metastasis, brain metastasis, liver metastasis, pleural effu-
sion, number of previous chemotherapy regimens,
response condition and rash inducing by gefitinib. Multi-
ple linear regression model was used to analysis factors
affecting tumor response rate (RR). The factors considered
for inclusion in the analyses were age, sex, smoking status,
histology type, bone metastasis, brain metastasis, liver
metastasis, pleural effusion, number of previous chemo-
therapy regimens and rash inducing by gefitinib.
Results
Overall efficacy
From Oct 2002 to Apr. 2006, 42 advanced NSCLC
patients with PS 3/4 received gefitinib 250 mg/day treat-
ment. The baseline demographic factors are showed [see
Additional file 1]. The median overall survival (MS) was
10.1 months (95% CI 3.4–16.8 months), and 1-year sur-
vival rate 45% in Figure 1. The median progress free sur-
vival (PFS) was 5.7 months (95% CI 4.5–6.9 months). In
objective efficacy evaluation, 17 cases (40.5%) had a par-
tial response (PR), 11 (26.2%) stable disease (SD), 7
(16.7%) progressive disease (PD), and 7 (16.7%) no
available data.
Factors that affect survival
Only response to gefitinib had a significant influence on
survival through Cox regression analysis [see Additional
file 2]. The MS was not related to age, sex, ECOG perform-
ance status, histology type, bone metastases, brain metas-
tases, liver metastases, pleural effusion, and prior
chemotherapy regimens.
Factors that affect objective efficacy
It could be seen that only skin rash after treatment were
associated with significantly better objective response rate
[see Additional file 3]. The objective response rate was not
related to age, sex, ECOG performance status, histology
type, bone metastases, brain metastases, liver metastases,
pleural effusion, and prior chemotherapy regimens.
Adverse events (AEs)
6 patients were not followed for AEs. Common AEs in 36
patients were listed [see Additional file 4], the most com-
mon AE were skin rash, followed by diarrhea and appetite
loss. There were very rare grade 3 or 4 AEs. No patients
withdrew from gefitinib treatment due to AE.
Discussion
Chemotherapy has its role in advanced NSCLC patients
with good PS, but patients with ECOG PS 3–4 are not suit-
able for any chemotherapy. Gefitinib is the treatment
choice for these special group patients because of the low
toxicity. Gefitinib had been used as first line treatment for
NSCLC patients with poor PS or refusal to chemotherapy.BMC Research Notes 2008, 1:102 http://www.biomedcentral.com/1756-0500/1/102
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The toxicity profile of gefitinib is clearly better than that
reported with chemotherapy. The main AEs were skin rash
and diarrhea, and most AEs were CTC grade 1 or 2, which
was similar to the patients with good PS in IDEAL-1 and
IDEAL-2 study [4,5].
In this study, histology type, sex, or smoking status had no
difference in objective response, but in some phase II tri-
als, adenocarcinoma, never smokers and female patients
had better response rate[6]. This may be due to small sam-
ple size or poor PS. In this trial, the objective response rate
and disease control rate were 40.5% and 66.7%, respec-
tively, higher than those of 18.4% and 54.4% in IDEAL-1
study, and 11.8% and 42.0% in IDEAL2 study. In IDEAL-
1 study, there were 102 Japanese patients, whose objective
response rate was 27.5%, similar to our results, suggesting
there might be ethnic differences in gefitinib efficacy.
Somatic mutations of the EGFR tyrosine kinase were
found in 15 of 58(25.9%) from Japan, 28 of 76(36.8%)
from China and 1 of 61(1.6%) from the United States[7-
9], which may explain the higher response rate in Asia
patients. In our patients, the skin rash induced with gefit-
inib was significantly associated with objective response,
and these usually occurs within 2 weeks after treatment,
they can be used as indicators for treatment efficacy. Sev-
enty-two advanced NSCLC patients with PS ≥ 2 and no
previous chemotherapy were given gefitinib 250 mg per
day in USA[10]. Objective response showed PR 4%, SD
46% and PD 26%. PFS and MS were 3.7 months and 6.3
months, respectively. It was drawn that Gefitinib demon-
strates modest efficacy and is well tolerated in advanced
NSCLC for patients with poor PS. Chang et al[11]
reported 52 patients with advanced NSCLC and with PS
3–4 received gefitinib treatment. The response rate was
25.0% and MS was 2.5 months (response group 9.1
months). Adverse events were mainly skin reactions and
diarrhea. Single gefitinib is worthy of testing in the future
for poor PS patients with advanced NSCLC, especially in
Asia.
PS was a significant prognostic factor in predicting sur-
vival. In our study, the MS was 10 months for patients
with PS 3–4, which was better than best supportive care.
The median survival was significantly related with gefit-
inib objective efficacy only, and no relation with sex, age,
Survival Function Figure 1
Survival Function.  The median overall survival (MS) was 10.1 months (95% CI 3.4–16.8 months), and 1-year survival rate 
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smoking status, histology type and prior chemotherapy
regimens.
In conclusion, gefitinib has clinically antitumor activity
and good tolerability in Chinese patients with advanced
NSCLC and poor PS. Formal clinical trial are warranted
for these special group patients.
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